9, RUE DE BITBOURG, LUXEMBOURG, N4
Announces a Change in its Executive Team
Q4 2025 and Full Year 2025 Financial Results
Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them
Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
Enters Supply and Commercialization Agreements for Canada and Australia & New Zealand Covering Multiple Biosimilar Candidates
Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
Announces Acquisition and Sale of Shares by ATP Holdings ehf.
Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
RW
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis